SMSPHARMA
OVERVALUEDSMS Pharmaceuticals Limited
Pharma · NSE
↓ 453.3% vs fair value
52W Low
₹188
+106.9% from low
52W High
₹434
-10.3% from high
Valuation Gauge
Current Price
₹389
Fair Value
₹70
Fair Value Analysis
₹70
Based on earnings growth potential for Pharma sector companies
Growth Valuation
100% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Mixed Signals
Profitability
ROE of 8.2% is below the Pharma sector benchmark of 18%
Debt & Leverage
D/E ratio of 0.4x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 55.3x trades at a significant premium to Pharma sector median (42x)
Cash Flow
Negative FCF of ₹-42 Cr — company is consuming more cash than it generates
Earnings Growth
5yr EPS CAGR of 3.6% is well below Pharma sector average of 15.3%
Dividend
Dividend yield of 0.1% is symbolic — low but positive
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
-1.1%
Free cash flow / market cap
Revenue Growth (YoY)
+49.5%
Year-on-year revenue change
Profit Growth (YoY)
-2.5%
Year-on-year PAT change
Operating Cash Flow
₹82 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹7
P/E Ratio
55.3x
P/B Ratio
4.9x
ROE
8.2%
ROCE
13.3%
Debt / Equity
0.44x
Beta
0.43
Div Yield
0.1%
FCF (Cr)
₹-42 Cr
Revenue (Cr)
₹779 Cr
EPS Growth 5Y
3.6%
Mkt Cap (Cr)
₹3,636 Cr
52W High
₹433.9
52W Low
₹188
Book Value/Share
₹79.6
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹897 Cr | ₹172 Cr | 19.0% | ₹90 Cr | ₹9.81 |
| 2025-03-31 | ₹783 Cr | ₹139 Cr | 18.0% | ₹69 Cr | ₹7.80 |
| 2024-03-31 | ₹709 Cr | ₹117 Cr | 16.0% | ₹50 Cr | ₹5.88 |
| 2023-03-31 | ₹522 Cr | ₹55 Cr | 10.0% | ₹-7 Cr | ₹-0.83 |
| 2022-03-31 | ₹520 Cr | ₹115 Cr | 22.0% | ₹62 Cr | ₹7.35 |
| 2021-03-31 | ₹563 Cr | ₹121 Cr | 22.0% | ₹63 Cr | ₹7.38 |
| 2020-03-31 | ₹412 Cr | ₹80 Cr | 19.0% | ₹32 Cr | ₹3.73 |
| 2019-03-31 | ₹465 Cr | ₹90 Cr | 19.0% | ₹40 Cr | ₹4.73 |
| 2018-03-31 | ₹463 Cr | ₹93 Cr | 20.0% | ₹32 Cr | ₹3.75 |
| 2017-03-31 | ₹438 Cr | ₹75 Cr | 17.0% | ₹28 Cr | ₹3.36 |
| 2016-03-31 | ₹611 Cr | ₹89 Cr | 15.0% | ₹41 Cr | ₹4.83 |
| 2007-03-31 | ₹193 Cr | ₹47 Cr | 25.0% | ₹25 Cr | ₹2.55 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86 | ₹469.7 | +81.7% | 7.3 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹79.5 | ₹237.8 | +66.6% | 19.6 | 5.2% | FAIRLY_VALUED |
Kilitch Drugs (India) Limited | ₹132.7 | ₹321 | +58.7% | 17.7 | 9.4% | UNDERVALUED |
Bal Pharma Limited | ₹69 | ₹147.5 | +53.2% | 12.8 | 12.6% | FAIRLY_VALUED |
Zydus Lifesciences | ₹868 | ₹1,502.2 | +42.2% | 17.6 | 19.9% | UNDERVALUED |
Natco Pharma | ₹1,030 | ₹1,597 | +35.5% | 11.8 | 18.0% | UNDERVALUED |
Jagsonpal Pharmaceuticals Limited | ₹190.6 | ₹275.2 | +30.7% | 30.8 | 20.1% | UNDERVALUED |
Lupin | ₹2,280 | ₹3,112 | +26.7% | 22.4 | 23.8% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant